| Issue Date | Title | Author(s) |
| 2021-08 | Overview of key molecular and pharmacological targets for diabetes and associated diseases | Shahcheraghi, SH; Aljabali, AAA; Al Zoubi, MS; Mishra, V; Charbe, NB; Haggag, YA; Shrivastava, G; Almutary, AG; Alnuqaydan, AM; Barh, D; Dua, K; Chellappan, DK; Gupta, G; Lotfi, M; Serrano-Aroca, Á; Bahar, B; Mishra, YK; Takayama, K; Panda, PK; Bakshi, HA; Tambuwala, MM |
| 2021-06 | Recent updates on animal models for understanding the etiopathogenesis of polycystic ovarian syndrome | Corrie, L; Gulati, M; Singh, SK; Kapoor, B; Khursheed, R; Awasthi, A; Vishwas, S; Chellappan, DK; Gupta, G; Jha, NK; Anand, K; Dua, K |
| 2021-09 | Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective | Chan, Y; Ng, SW; Singh, SK; Gulati, M; Gupta, G; Chaudhary, SK; Hing, GB; Collet, T; MacLoughlin, R; Löbenberg, R; Oliver, BG; Chellappan, DK; Dua, K |
| 2021-09 | Inhaled nano-based therapeutics for inflammatory lung diseases: Recent advances and future prospects | Gulati, N; Chellappan, DK; MacLoughlin, R; Dua, K; Dureja, H |
| 2021-02 | Targeting eosinophils in respiratory diseases: Biological axis, emerging therapeutics and treatment modalities. | Lee, L-Y; Hew, GSY; Meenu,; Shukla, SD; Satija, S; Khurana, N; Anand, K; Dureja, H; Singh, SK; Mishra, V; Singh, PK; Gulati, M; Prasher, P; Aljabali, AAA; Tambuwala, MM; Thangavelu, L; Panneerselvam, J; Gupta, G; Zacconi, FC; Shastri, M; Jha, NK; Xenaki, D; MacLoughlin, R; Oliver, BG; Chellappan, DK; Dua, K |
| 2021-11 | Bacterial biofilms associated skin disorders: Pathogenesis, advanced pharmacotherapy and nanotechnology-based drug delivery systems as a treatment approach | Vyas, T; Rapalli, VK; Chellappan, DK; Dua, K; Dubey, SK; Singhvi, G |
| 2023-04-05 | Senolytics: Opening avenues in drug discovery to find novel therapeutics for Parkinson's Disease. | Kakoty, V; Kalarikkal Chandran, S; Gulati, M; Goh, BH; Dua, K; Kumar Singh, S |
| 2018-03 | Transcriptional regulation of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by the chelator, Dp44mT. | Moussa, RS; Kovacevic, Z; Bae, D-H; Lane, DJR; Richardson, DR |
| 2022-04-01 | Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fate | Sheikholeslami, B; Lam, NW; Dua, K; Haghi, M |
| 2022-04-01 | PEPTIDYLARGININE DEIMINASE-4: MEDICO-FORMULATIVE STRATEGY TOWARDS MANAGEMENT OF RHEUMATOID ARTHRITIS | Thirugnanasambandham, I; Radhakrishnan, A; Kuppusamy, G; Singh, SK; Dua, K |
